The global atopic dermatitis market valued at US$ 5.9 Billion in 2021 and in 2022 be valued at US$ 7.3 Billion. During the 2022-2032 period of assessment, demand is expected to rise at a 24% value CAGR, likely to reach US$ 62.7 Billion by the end of the said forecast period. The atopic dermatitis market refers to the global market for products and treatments related to atopic dermatitis, also known as eczema. Atopic dermatitis is a chronic inflammatory skin condition characterized by dry, itchy, and inflamed skin. It affects a significant number of people worldwide, including both children and adults.
The market for atopic dermatitis is driven by several factors, including the increasing prevalence of the condition, rising awareness among patients, and advancements in treatment options. The market includes a wide range of products such as topical corticosteroids, topical calcineurin inhibitors, systemic immunosuppressants, biologics, and emollients
Download Free Sample Copy of this Report –https://www.factmr.com/connectus/sample?flag=S&rep_id=4603
Global Atopic Dermatitis Drugs Market Segmentation
Fact.MR has studied the global atopic dermatitis drugs market with detailed segmentation on the basis product type, application and key regions.
- By Drug Class :
- Corticosteroids
- PDE4 Inhibitors
- Biologics
- Skin Barrier Emollients
- CNI Immunosuppressants
- Others
- By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Key Regions :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Competitive Landscape
The global atopic dermatitis drugs market is dominated by six key players. These are Mylan M.V., Pfizer Inc., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd, Sanofi, and Novartis AG.
Investment in research and development of new pharmaceutical drugs is the key strategy for the market expansion of the aforementioned companies. Product Development to Remain a Growth Lever for Market Players. Some of the developments in the market are
For example :
- Sanofi Genzyme manufactures the Biologics drug DUPIXNET ® which cures skin lesions and reduces itching.It does so by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. These proteins are key contributors of type-2 inflammation which occurs in atopic dermatitis.
- Pfizer Inc., manufactures Eucrisa (crisaborole) which consists of PDE4 Inhibitors to treat skin ailments, particularly Eczema.The ointment targets the enzyme Phosphodiesterase-4, or PDE4, by blocking the over reactive enzymes within skin cells to prevent inflammation.
Key Companies Profiled
- Mylan M.V.
- Pfizer Inc.
- LEO Pharma A/S
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Novartis AG.
After reading the Market insights of Atopic Dermatitis Report, readers can:
- Understand the drivers, restraints, opportunities and trends affecting the Sales of market.
- Analyze key regions holding significant share of total Atopic Dermatitis market revenue.
- Study the growth outlook of Atopic Dermatitis market scenario, including production, consumption, history and forecast.
- Learn consumption pattern and impact of each end use & supply side analysis of Atopic Dermatitis market.
- Investigate the recent R&D projects performed by each market player & competitive analysis of Atopic Dermatitis Market Players.
How Fact.MR Assists in Making Strategic Moves For Atopic Dermatitis Market Manufacturer?
- The data provided in the Atopic Dermatitis market report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.
- The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by market players. The main motive of this report is to assist enterprises to make data-driven decisions and strategize their business moves.